Article Text

other Versions

PDF
Meningoencephalitis of unknown origin: investigation of prognostic factors and outcome using a standard treatment protocol
  1. M. Lowrie, MA VetMB MVM DipECVN MRCVS,
  2. P. M. Smith, BSc BVM&S PhD DipECVN MRCVS and
  3. L. Garosi, DVM DipECVN MRCVS
  1. Davies Veterinary Specialists, Manor Farm Business Park, Higham Gobion, Hitchin, Hertfordshire SG5 3HR, UK;
  1. E-mail for correspondence: mll{at}vetspecialists.co.uk

Abstract

Meningoencephalitis of unknown origin (MUO) is a common inflammatory CNS disease in dogs, with a variable and unpredictable outcome. MRI and cerebrospinal fluid (CSF) features were prospectively evaluated to establish their utility as prognostic markers for predicting mortality, relapse and long-term outcome in 39 dogs with MUO. MRI and CSF analysis were performed at initial diagnosis and three months into treatment with prednisolone and cytosine arabinoside. When possible, MRI was repeated every 12 months thereafter. Median survival time was 26 days. All deaths occurred within 52 days of diagnosis (22/39; 56 per cent). One-third (13/39) died within 72 hours of diagnosis. Outcome was good or excellent in 12/17 surviving dogs. Loss of the cerebral sulci and foramen magnum herniation on MRI were associated with increased risk of mortality. An abnormal CSF analysis at the three-month re-examination was associated with increased risk of relapse (P=0.04). The combination of MRI and CSF analysis provided a greater sensitivity for predicting relapse than one modality alone. Discontinuing treatment before MRI lesions resolved always resulted in relapse. The presence of certain MRI characteristics may indicate an increased risk of mortality. Dogs alive three months following diagnosis have a very low risk of death due to MUO.

  • Magnetic resonance imaging (MRI)
  • Central nervous system (CNS)
  • Dogs
  • Cerebrospinal fluid
  • Meningoencephalitis
  • Inflammation
  • Accepted February 15, 2013.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.